NDA 208051/S-007

SUPPLEMENT APPROVAL/
FULFILLMENT OF POSTMARKETING
COMMITMENT

Puma Biotechnology, Inc.
Attention: Jesse Ho, PharmD
Associate Director, Regulatory Science
10880 Wilshire Blvd., Suite 2150
Los Angeles, CA 90024

Dear Dr. Ho:

Please refer to your supplemental new drug application dated and received on January 30, 2020, and your amendments, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Nerlynx (neratinib maleate) tablets.

This Prior Approval supplemental new drug application provides for updates to section 14 of the U.S. prescribing information to include the final overall survival analysis based on results from ExteNET clinical trial. In addition, AST was added to the dose modifications for hepatotoxicity in Table 7.

APPROVAL & LABELING

We have completed our review of this application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling.

WAIVER OF ½ PAGE LENGTH REQUIREMENT FOR HIGHLIGHTS

Please note that we have previously granted a waiver of the requirements of 21 CFR 201.57(d)(8) regarding the length of Highlights of Prescribing Information.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at FDA.gov.[1] Content of labeling must be identical to the enclosed labeling Prescribing Information and Patient Package Insert, with the addition of any labeling changes in pending "Changes Being Effected" (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

[1] http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm

Information on submitting SPL files using eList may be found in the guidance for industry *SPL Standard for Content of Labeling Technical Qs and As*.[2]

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that include labeling changes for this new drug application (NDA), including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in Microsoft Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes. To facilitate review of your submission(s), provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

REQUIRED PEDIATRIC ASSESSMENTS

Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), all applications for new active ingredients (which includes new salts and new fixed combinations), new indications, new dosage forms, new dosing regimens, or new routes of administration are required to contain an assessment of the safety and effectiveness of the product for the claimed indication in pediatric patients unless this requirement is waived, deferred, or inapplicable.

We are waiving the pediatric study requirement for these applications because necessary studies are impossible or highly impracticable. Breast cancer is extremely rare in pediatric patients.

FULFILLMENT OF POSTMARKETING COMMITMENT

We also refer to your submission dated January 30, 2020, containing the final report for the following postmarketing commitment listed in the July 17, 2017, approval letter.

3223-3 Submit the overall survival (OS) data and results from Trial 3144A2-3004 WW, ExteNET, “A Randomized, Double-Blind, Placebo-Controlled Trial of Neratinib (HKI-272) After Trastuzumab in Women with Early-Stage HER-2/neu Overexpressed/Amplified Breast Cancer”.

We have reviewed your submission and conclude that the above postmarketing commitment is fulfilled.

[2] We update guidances periodically. For the most recent version of a guidance, check the FDA Guidance Documents Database https://www.fda.gov/RegulatoryInformation/Guidances/default.htm.

This completes all of your postmarketing requirements and postmarketing commitments acknowledged in our July 17, 2017, approval letter.

PROMOTIONAL MATERIALS

You may request advisory comments on proposed introductory advertising and promotional labeling. For information about submitting promotional materials, see the final guidance for industry *Providing Regulatory Submissions in Electronic and Non-Electronic Format-Promotional Labeling and Advertising Materials for Human Prescription Drugs.*[3]

You must submit final promotional materials and Prescribing Information, accompanied by a Form FDA 2253, at the time of initial dissemination or publication [21 CFR 314.81(b)(3)(i)]. Form FDA 2253 is available at FDA.gov.[4] Information and Instructions for completing the form can be found at FDA.gov.[5]

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, contact Amy Tilley, Regulatory Project Manager, at amy.tilley@fda.hhs.gov or 301.796.3994.

Sincerely,

{See appended electronic signature page}

Laleh Amiri-Kordestani, MD
Acting Director
Division of Oncology 1
Office of Oncologic Diseases
Center for Drug Evaluation & Research

ENCLOSURES:

- Content of Labeling
  - Prescribing Information
  - Patient Package Insert

[3] For the most recent version of a guidance, check the FDA guidance web page at https://www.fda.gov/media/128163/download.
[4] http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM083570.pdf
[5] http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM375154.pdf

---

This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.

/s/

LALEH AMIRI KORDESTANI
07/29/2020 11:52:41 AM